Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameMP Cardioflow-B
Stock Code02160
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專注於心臟瓣膜疾病領域創新的經導管及手術解決方案的研發和商業化,主要產品為TAVI產品VitaFlow及VitaFlow II,並布局TMV、TTV等產品管線。
Listing Date2021-02-04
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東新區張江高科技園區張東路1601號
Business Address (Hong Kong)香港銅鑼灣希慎道33號利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitecardioflowmedtech.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 12.20 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 12,200
Par ValueTo be extracted
Offer Period2021-01-26 to 2021-01-29
Global Offering Shares205,620,000 shares
HK Public Offer Shares (Initial)20,562,000 shares (10.0%)
Public Offer Lots (Initial)20,562lots (Pool A10,281lots,Pool B10,281lots)
International Placing Shares (Initial)185,058,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO2,366,167,020 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share38.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,508,564,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 12,200
2 lots 2,000 HK$ 24,400
3 lots 3,000 HK$ 36,600
4 lots 4,000 HK$ 48,800
5 lots 5,000 HK$ 61,000
6 lots 6,000 HK$ 73,200
7 lots 7,000 HK$ 85,400
8 lots 8,000 HK$ 97,600
9 lots 9,000 HK$ 109,800
10 lots 10,000 HK$ 122,000
15 lots 15,000 HK$ 183,000
20 lots 20,000 HK$ 244,000
25 lots 25,000 HK$ 305,000
30 lots 30,000 HK$ 366,000
35 lots 35,000 HK$ 427,000
40 lots 40,000 HK$ 488,000
45 lots 45,000 HK$ 549,000
50 lots 50,000 HK$ 610,000
60 lots 60,000 HK$ 732,000
70 lots 70,000 HK$ 854,000
80 lots 80,000 HK$ 976,000
90 lots 90,000 HK$ 1,098,000
100 lots 100,000 HK$ 1,220,000
100 lots 100,000 HK$ 1,220,000
150 lots 150,000 HK$ 1,830,000
150 lots 150,000 HK$ 1,830,000
200 lots 200,000 HK$ 2,440,000
200 lots 200,000 HK$ 2,440,000
250 lots 250,000 HK$ 3,050,000
300 lots 300,000 HK$ 3,660,000
350 lots 350,000 HK$ 4,270,000
400 lots 400,000 HK$ 4,880,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
450 lots 450,000 HK$ 5,490,000
500 lots 500,000 HK$ 6,100,000
600 lots 600,000 HK$ 7,320,000
700 lots 700,000 HK$ 8,540,000
800 lots 800,000 HK$ 9,760,000
900 lots 900,000 HK$ 10,980,000
1,000 lots 1,000,000 HK$ 12,200,000
2,000 lots 2,000,000 HK$ 24,400,000
3,000 lots 3,000,000 HK$ 36,600,000
3,000 lots 3,000,000 HK$ 36,600,000
4,000 lots 4,000,000 HK$ 48,800,000
5,000 lots 5,000,000 HK$ 61,000,000
6,000 lots 6,000,000 HK$ 73,200,000
7,000 lots 7,000,000 HK$ 85,400,000
8,000 lots 8,000,000 HK$ 97,600,000
9,000 lots 9,000,000 HK$ 109,800,000
10,281 lots 10,281,000 HK$ 125,428,200
261,865 lots 261,865,757 HK$ 3,194,762,235

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 2.08B
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +351%

Valuation & Financials

Market Cap (at Offer Price)HK$ 28,867,237,644
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣144.5百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Profit for the year -61,263-544,722
Balance Sheet
Item 201820192020-07
Cash and cash equivalents 61,418611,873
Trade and bills receivables 975,617724,618
Inventories 87,085497,827
Total current assets 748,891983,691
Total assets 448,897826,893
Total current liabilities 862,758966,796
Total liabilities 874,804682,809
Total equity 872,888841,882
Interest-bearing borrowings 020,0000
Cash Flow Statement
Item 201820192020-07
Net cash from operating activities -706,816-642,837
Net cash from investing activities -740,715-756,871
Net cash from financing activities 717,776643,751
Net increase in cash -696,856746,752
Purchase of PP&E -4,077-7,364-5,732
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 18.82
First Day OpenHK$ 21.5
First Day Change54.26%
First Day Volume186931000.0
First Day Turnover3780700000.0
Use of Proceeds
1、30.0%(或約706.8百萬港元)將被分配予我們的核心產品(即VitaFlowTMII); 2、3.4%(或約80.1百萬港元)將被分配予我們首款商業化TAVI產品(即VitaFlowTM); 3、27.0%(或約636.1百萬港元)將被分配予我們目前產品管線的其他產品; 4、15.0%(或約353.4百萬港元)將獲分配用于為通過并購、授權引進或股權投資等方式與包括醫療器械企業及研究機構在內的全球賦能者合作擴展我們的產品組合提供資金; 5、14.6%(或約344.0百萬港元)將用于擴大我們的產能并提高我們生產VitaFlowTM及VitaFlowTMII的能力; 6、10.0%(或約235.6百萬港元)將用作我們的營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (3)
J.P. Morgan Securities (Far East) Limited CE AAB026 Citigroup Global Markets Asia Limited CE AAA137 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (3)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Citigroup Global Markets Asia Limited CE AAA137 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Citigroup Global Markets Asia Limited CE AAA137 中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (3)
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Citigroup Global Markets Asia Limited CE AAA137 中国国际金融香港证券有限公司 CE AEN894

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 3W Funds 38,759,400 HKD — 1.50% — 6 months 2021-08-04
2 CDG Group Fund L.P. 38,759,400 HKD — 1.50% — 6 months 2021-08-04
3 CPE Greater China Enterprises Growth Fund 155,062,000 HKD — 6.20% — 6 months 2021-08-04
4 GIC Private Limited 77,531,000 HKD — 3.10% — 6 months 2021-08-04
5 Hillhouse Funds 116,302,600 HKD — 4.60% — 6 months 2021-08-04
6 Indus Funds 38,759,400 HKD — 1.50% — 6 months 2021-08-04
7 Lake Bleu Prime Healthcare Master Fund Limited 77,531,000 HKD — 3.10% — 6 months 2021-08-04
8 Snow Lake China Master Fund, Ltd. 77,531,000 HKD — 3.10% — 6 months 2021-08-04
9 Tybourne Funds 38,759,400 HKD — 1.50% — 6 months 2021-08-04
10 Woodline Master Fund LP 38,759,400 HKD — 1.50% — 6 months 2021-08-04
11 WT China Focus Fund 38,759,400 HKD — 1.50% — 6 months 2021-08-04
12 Yi Fang Da Brocade Inv. Limited 38,759,400 HKD — 1.50% — 6 months 2021-08-04
13 保银资产管理有限公司 38,759,400 HKD — 1.50% — 6 months 2021-08-04
14 华夏基金管理有限公司 38,759,400 HKD — 1.50% — 6 months 2021-08-04
15 昆仑集团有限公司 38,759,400 HKD — 1.50% — 6 months 2021-08-04
16 泰康人寿保险有限责任公司 77,531,000 HKD — 3.10% — 6 months 2021-08-04

Directors & Management

PositionChinese nameEnglish Name
Chairman羅七一—
Company Secretary李香梅、陳濼而—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東微創醫療通過Shanghai MicroPort於上市後持有約45.59%權益;上海鏵浩8.10%、中金康瑞7.67%、Qianyi Investment 6.34%。
About this page

This page shows MP Cardioflow-B (02160) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect